AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial
Fibrillation” provides recommendations to guide clinicians in the treatment of patients with …

Currently licenced direct oral anticoagulants selectively target thrombin (eg, dabigatran) or
coagulation factor Xa (eg, apixaban, betrixaban, edoxaban, and rivaroxaban). Designed to …

This article is published as part of a supplement sponsored by Kidney Disease: Improving
Global Outcomes (KDIGO). The opinions or views expressed in this supplement are those of …

Background In patients with normal renal function or early stage CKD, the risk-benefit profile
of direct oral anticoagulants (DOACs) is superior to that of vitamin K antagonists (VKAs). In …

Background: Effects of oral anticoagulation in chronic kidney disease (CKD) are uncertain.
Purpose: To evaluate the benefits and harms of vitamin K antagonists (VKAs) and non …

Oral anticoagulants are commonly used drugs in patients with CKD and patients with ESKD
to treat atrial fibrillation to reduce stroke and systemic embolism. Some of these drugs are …

In the absence of robust evidence to guide clinical decision-making, the optimal approach to
prevent stroke and systemic embolism in haemodialysis (HD) patients with atrial fibrillation …

Objective To assess the association between anticoagulation, ischaemic stroke,
gastrointestinal and cerebral haemorrhage, and all cause mortality in older people with atrial …

Background There is limited evidence on the effectiveness and safety of direct-acting oral
anticoagulants in patients with nonvalvular atrial fibrillation (NVAF) and advanced chronic …

Rationale & Objective Direct oral anticoagulants (DOACs) have progressively replaced
vitamin K antagonists (VKAs) for stroke prevention in patients with nonvalvular atrial …